PRPO Precipio, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1043961 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.8%
TTM net income YoY8.8%
TTM EPS YoY27.2%
Revenue 3-yr CAGR27.9%
Net income 3-yr CAGR—
Margins
Gross margin44.6%
Operating margin-5.3%
Net margin-4.1%
FCF margin5.0%
EBITDA margin-1.1%
Returns
ROE-8.0%
ROA-5.3%
ROIC (approx.)-10.1%
Asset turnover1.30x
Leverage & solvency
Liabilities / assets31.5%
Debt / equity0.02x
Current ratio1.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.49x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $24.05M | $18.53M |
| Cost of revenue | $13.34M | $10.97M |
| Gross profit | $10.71M | $7.56M |
| R&D expense | $1.60M | $1.30M |
| Operating income | -$1.20M | -$4.22M |
| Pretax income | -$363,000 | -$4.29M |
| Income tax | $0 | $0 |
| Net income | -$363,000 | -$4.29M |
| EBITDA | $43,000 | -$3.02M |
| EPS (basic) | -0.23 | -2.93 |
| EPS (diluted) | -0.23 | -2.93 |
| Weighted avg. shares (diluted) | 1.61M | 1.47M |
| Balance sheet | ||
| Cash & equivalents | $2.65M | $1.39M |
| Receivables | $1.98M | $799,000 |
| Inventory | $935,000 | $724,000 |
| Current assets | $6.04M | $3.45M |
| PP&E, net | $729,000 | $719,000 |
| Intangibles | $10.92M | $11.87M |
| Total assets | $21.32M | $17.00M |
| Current liabilities | $3.75M | $4.27M |
| Short-term debt | $30,000 | $297,000 |
| Long-term debt | $47,000 | $77,000 |
| Total debt | $77,000 | $374,000 |
| Total liabilities | $6.76M | $4.90M |
| Shareholders' equity | $14.56M | $12.09M |
| Net debt | -$2.57M | -$1.01M |
| Shares outstanding | 1.78M | 1.49M |
| Cash flow statement | ||
| Operating cash flow | $685,000 | $439,000 |
| Capital expenditure | $326,000 | $223,000 |
| Free cash flow | $359,000 | $216,000 |
| Investing cash flow | -$326,000 | -$223,000 |
| Financing cash flow | $903,000 | -$329,000 |
| Depreciation & amortization | $1.25M | $1.20M |
| Stock-based compensation | $1.21M | $1.49M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.